Summit Master_rgb_png.png
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
15 avr. 2019 02h00 HE | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Presented In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID...
Summit Master_rgb_png.png
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
14 avr. 2019 07h42 HE | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 ...
Summit Master_rgb_png.png
Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
03 avr. 2019 07h00 HE | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae   Data to be Presented in Oral Session at...
Summit Master_rgb_png.png
Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference
02 avr. 2019 07h00 HE | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference Oxford, UK, and Cambridge, MA, US, 2 April...
Summit Master_rgb_png.png
Award of Share Options
29 mars 2019 13h45 HE | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Award of Share Options Oxford, UK, and Cambridge, MA, US, 29 March 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in...
Summit Master_rgb_png.png
Award of Share Options
29 mars 2019 13h45 HE | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Award of Share Options Oxford, UK, and Cambridge, MA, US, 29 March 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new...
Summit Master_rgb_png.png
Filing of Annual Report on Form 20-F
29 mars 2019 07h15 HE | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics Files US Annual Report on Form 20-F Oxford, UK, and Cambridge, MA, US, 29 March 2019 – Summit Therapeutics plc (NASDAQ:...
Summit Master_rgb_png.png
Final Results
27 mars 2019 07h00 HE | Summit Therapeutics plc
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2019 and Operational...
Summit Master_rgb_png.png
Notice of Results
25 mars 2019 07h00 HE | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2019 Oxford, UK, and Cambridge,...
Summit Master_rgb_png.png
Summit Therapeutics to Present at Upcoming Conferences
18 mars 2019 07h00 HE | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at Upcoming Conferences Oxford, UK, and Cambridge, MA, US, 18 March 2019 – Summit Therapeutics plc...